Status:
COMPLETED
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
Lead Sponsor:
GlaxoSmithKline
Conditions:
Meningococcal Disease
Infections, Meningococcal
Eligibility:
All Genders
2-23 years
Brief Summary
This safety surveillance study of GlaxoSmithKline's quadrivalent meningococcal ACWY conjugate vaccine (Meningococcal quadrivalent CRM-197) among children 2 months through 23 months of age is a post-ma...
Eligibility Criteria
Inclusion
- children 2-23 months of age at the time of MenACWY-CRM vaccination
- hold KPSC membership at the time of MenACWY-CRM vaccination
- vaccinated with MenACWY-CRM during the study period in KPSC
Exclusion
- None
Key Trial Info
Start Date :
December 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 29 2017
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT02287688
Start Date
December 1 2014
End Date
November 29 2017
Last Update
October 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Pasadena, California, United States, 91101